In recent months, the medical benefits of cannabis have been all over the news. With reports that cannabis oil can reduce and even stop seizures, help patients with memory loss like dementia and Alzheimer’s, and even help to reduce pain associated with chronic illness, it makes sense that more and more biotech companies would be looking to get in on the market.
Earlier this week biotech newcomer AXIM Biotechnologies, Inc. (OTCQX: AXIM) announced that they would be teaming up with a United States based API (Active Pharmaceutical Ingredient) production company to further their production and creation of a dronabinol based functional chewing gum. AXIM is a forerunner in cannabinoid research and have been working for years to help develop solutions like Marinol, a gel capsule containing cannabinoid to help with things like nausea associated with AIDS treatment and chemotherapy.
AXIM has long been part of the cannabinoid production world. They have worked for years to help create cannabis-based pharmaceutical, nutraceutical, and cosmetic products. AXIM is currently looking to pair with the API company in order to produce a time released cannabinoid chewing gum that will reduce the side effects that are currently associated with Marinol. Marinol, at this time, is the only cannabis based drug that is approved by the FDA and is available in the US.
What AXIM Hopes to Accomplish
The new dronabinol chewing gum that AXIM hopes to market is the bioequivalent to Marinol, but it does not come with the scary side effects. The gum would be used to help treat patients that are suffering from nausea and vomiting induced by AIDS and chemotherapy. The gum would be time released and would help to bypass symptoms of Marinol like impaired thinking and other adverse reactions that have been experienced while taking the drug.
There is no doubt that cannabis does have the properties that would help to alleviate a myriad of medical conditions and AIXM is seeking to make this a more widely accepted concept. The gum is time released so it would be able to effectively bypass the first pass metabolism of the liver so that the side effects would be greatly lessened for those using the gum.
About the Deal
The API company is namely being employed to supply AXIM with a synthetic dronabinol (delta-9-THC) that is going to be used in the clinical trials before the gum goes to market. The dronabinol is going to be used in the clinical trials at which time data is to be collected in order to complete a bioequivalency study to present to the FDA. AXIM hopes that the data collected will help to get the drug approved by the FDA so that it can go into mass production to be introduced to the market.
“This is a substantial step forward to improving the current product offerings on the market for patients who are suffering these types of symptoms,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “Currently there is a 40% drop-out rate of patients who take Marinol, we are hopeful that our innovative chewing gum delivery method will lead to decreased side effects and allow for a better quality of life for these patients.”
It has long been known that cannabis does have certain properties that help alleviate medical issues in humans. Currently, medical marijuana is available in several of the 50 states and many doctors do prescribe to help alleviate things like chronic pain, nausea, and even memory loss. Cannabis based drugs are accepted in other countries and currently the US is looking toward creating new drugs that harness the good qualities of cannabis and bypass the bad.
AXIM hopes that this new gum will help to reduce side effects that have been seen with the use of Marinol without bypassing any of the good properties of the drug. Marinol has been found to be effective, even with the side effects, but for some risking these side effects is simply too great. The gum would provide an alternative to those that do not feel safe using Marinol in its current state.
At this time, there is no proposed release date or timeline that would indicate when the FDA would take a look at the drug and potentially approve it. No matter how long it takes, an effective and safe alternative to Marinol is at hand and it means a great deal to those that are in need.
About the Author
Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/